BioCentury
ARTICLE | Clinical News

FX006: Phase II started

May 18, 2015 7:00 AM UTC

Flexion began a double-blind, U.S. Phase II trial to compare a single dose of 40 mg intra-articular FX006 vs. immediate-release TCA in 124 active military and medically retired veteran patients with p...